UK markets closed
  • NIKKEI 225

    28,708.58
    -546.97 (-1.87%)
     
  • HANG SENG

    26,017.53
    -118.49 (-0.45%)
     
  • CRUDE OIL

    81.64
    -1.78 (-2.13%)
     
  • GOLD FUTURES

    1,781.30
    -3.60 (-0.20%)
     
  • DOW

    35,494.53
    -114.81 (-0.32%)
     
  • BTC-GBP

    45,737.96
    -2,643.55 (-5.46%)
     
  • CMC Crypto 200

    1,494.28
    -40.37 (-2.63%)
     
  • ^IXIC

    15,179.22
    +57.54 (+0.38%)
     
  • ^FTAS

    4,102.33
    -16.45 (-0.40%)
     

Worldwide Cardiac Pacemaker Devices Industry to 2028 - Featuring Biotronik, Abbott Laboratories and Lepu Medical Among Others

·5-min read

Dublin, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Cardiac Pacemaker Devices Market by Product, Indication, End User - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

The global cardiac pacemaker devices market is expected to grow at a CAGR of 3.1% from 2021 to 2028 to reach ~$4.34 billion by 2028.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the cardiac pacemaker devices market is mainly attributed to the rising geriatric population, rise in obesity, sedentary lifestyle, & excessive consumption of alcohol, increasing burden of cardiovascular diseases, and technological advancements such as miniaturization, complete magnetic resonance imaging (MRI) compatibility, wireless remote monitoring features, and innovative leadless pacemakers. Moreover, the availability of favorable reimbursement scenarios in the U.S. and U.K. serves as a significant growth opportunity for the growth of this market.

Based on product, the cardiac pacemakers segment is expected to show the highest growth during the forecast period. This is due to the rising adoption of cardiac pacemakers for the prevention & better management of sudden cardiac arrest and the availability of favorable reimbursement scenarios. Apart from this, the overall rise in the prevalence of cardiovascular disorders with an increase in life expectancy, adoption of a sedentary lifestyle, unhealthy food, and rising demand for innovative products with technological advancements will further drive the growth of the cardiac pacemaker devices market.

Based on end user, the hospitals & clinics segment is expected to account for the largest share in 2021. Factors contributing to the large share of this segment include a large pool of patients with cardiovascular diseases visiting the hospitals for diagnosis & treatment and availability of better healthcare facilities in hospitals along with their wide presence and easy accessibility.

An in-depth analysis of the geographical scenario of the cardiac pacemaker devices market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to account for the largest share of the cardiac pacemaker devices market in 2021, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the global cardiac pacemaker devices market are Medtronic Public Limited Company (Ireland), Boston Scientific Corporation (U.S.), Biotronik SE & Co. KG (Germany), Abbott Laboratories (U.S.), MEDICO S.p.A. (Italy), Shree Pacetronix Ltd. (India), Lepu Medical Group (China), Osypka Medical GmbH (Germany), OSCOR Inc. (U.S.), and MicroPort Scientific Corporation (China), among others.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Rising Geriatric Population
4.2.2. Increasing Burden of Cardiovascular Diseases
4.2.3. Rise in Obesity, Sedentary Lifestyle, & Excessive Consumption of Alcohol
4.2.4. Technological Advancements
4.3. Restraints
4.3.1. Increase in Reported Cases of Cardiac Pacemaker Malfunction & Product Recalls
4.4. Opportunities
4.4.1. Favourable Reimbursement Scenario in the U.S.
4.5. Challenges
4.5.1. Shortage of Medical Professionals
4.6. Trends
4.6.1. Use of MRI-Safe and MRI Conditional Pacemakers
4.7. Impact of Covid 19 Pandemic on Cardiac Pacemaker Devices Market

5. Regulatory Analysis - Cardiac Pacemaker Devices Market
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Latin America and the Middle East & Africa

6. Pricing Analysis - Cardiac Pacemaker Devices Market
6.1. Introduction

7. Global Cardiac Pacemaker Devices Market, by Type
7.1. Introduction
7.2. Cardiac Pacemakers
7.2.1. Implantable Pacemakers
7.2.1.1. Dual-chamber Pacemakers
7.2.1.2. Single-chamber Pacemakers
7.2.1.3. Biventricular Pacemakers
7.2.2. External Pacemakers
7.3. Pacing Leads
7.4. Pacing Analyzers

8. Global Cardiac Pacemaker Devices Market, by Indication
8.1. Introduction
8.2. Arrhythmia
8.3. Congestive Heart Failure
8.4. Other Indications

9. Global Cardiac Pacemaker Devices Market, by End User
9.1. Introduction
9.2. Hospitals & Clinics
9.3. Ambulatory Surgery Centers
9.4. Other End Users

10. Cardiac Pacemaker Devices Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe (RoE)
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific (RoAPAC)
10.5. Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2020)
11.4.1. Medtronic Public Limited Company (Ireland)
11.4.2. Abbott Laboratories (U.S.)
11.4.3. Boston Scientific Corporation (U.S.)

12. Company Profiles
12.1. Medtronic Public Limited Company
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Strategic Developments
12.2. Boston Scientific Corporation
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.3. Biotronik SE & Co. KG
12.3.1. Business Overview
12.3.2. Product Portfolio
12.4. Abbott Laboratories
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.5. MEDICO S.p.A.
12.5.1. Business Overview
12.6. Shree Pacetronix Ltd.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.4. Product Portfolio
12.7. Lepu Medical Group
12.7.1. Business Overview
12.7.2. Product Portfolio
12.8. Osypka Medical GmbH
12.8.1. Business Overview
12.8.2. Product Portfolio
12.9. OSCOR Inc.
12.9.1. Business Overview
12.9.2. Product Portfolio
12.10. MicroPort Scientific Corporation
12.10.1. Business Overview
12.10.2. Financial Overview
12.10.4. Product Portfolio

13. Appendix
13.1. Questionnaire
13.2. Available Customization

For more information about this report visit https://www.researchandmarkets.com/r/75yjl8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting